| scholarly article | Q13442814 |
| P50 | author | Hannelore Ehrenreich | Q1575862 |
| Anthony Cerami | Q4772238 | ||
| Anna-Leena Sirén | Q18224131 | ||
| Olaf Gefeller | Q40027859 | ||
| Michael Brines | Q55172197 | ||
| Piotr Lewczuk | Q58229544 | ||
| P2093 | author name string | Michael Stiefel | |
| Wolfgang Poser | |||
| Lukas Cepek | |||
| Martin Hasselblatt | |||
| Eckart Rüther | |||
| Matthias Bohn | |||
| Thomas C Wessel | |||
| Hilmar Prange | |||
| Norbert Breiter | |||
| Sonja Jacob | |||
| Marc De Ryck | |||
| Christoph Dembowski | |||
| Christoph Gleiter | |||
| Friederike Knerlich | |||
| Loretta Itri | |||
| Hans-Heino Rustenbeck | |||
| Michael Kochen | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 495-505 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Molecular Medicine | Q6895961 |
| P1476 | title | Erythropoietin therapy for acute stroke is both safe and beneficial | |
| P478 | volume | 8 |
| Q28574476 | A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain |
| Q30950859 | A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia |
| Q43606194 | A pilot study of darbepoetin alfa for prophylactic neuroprotection in aortic surgery |
| Q88201024 | A pilot study of the effect of intravenous erythropoetin on improvement of visual function in patients with recent indirect traumatic optic neuropathy |
| Q44296616 | A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. |
| Q34171042 | A systematic review and meta-analysis of erythropoietin in experimental stroke |
| Q43281704 | AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease |
| Q36124238 | Activating mitochondrial function and haemoglobin expression with EH-201, an inducer of erythropoietin in neuronal cells, reverses memory impairment |
| Q36449204 | Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I |
| Q35017110 | Age-dependent astroglial vulnerability to hypoxia and glutamate: the role for erythropoietin |
| Q34079647 | Agile delivery of protein therapeutics to CNS |
| Q49375977 | Alternative Erythropoietin Receptors in the Nervous System |
| Q37883005 | Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches |
| Q33961569 | Anemia is associated with the progression of white matter disease in older adults with high blood pressure: the cardiovascular health study |
| Q33718009 | Angiogenesis, neurogenesis and brain recovery of function following injury |
| Q27025091 | Animal models of traumatic brain injury |
| Q40009474 | Antiapoptotic properties of erythropoietin: novel strategies for protection of retinal pigment epithelial cells |
| Q41307431 | Apoptosis induced by parasitic diseases |
| Q48924173 | Approaches to neuroprotective and reperfusion injury therapy |
| Q36070895 | Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report. |
| Q35144156 | Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. |
| Q24795623 | Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice |
| Q35855561 | Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice |
| Q81954432 | Attenuation of monocyte proinflammatory cytokine responses to Neisseria meningitidis in children by erythropoietin |
| Q37781412 | Bench to bedside: A role for erythropoietin in sepsis. |
| Q36633772 | Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care |
| Q39206268 | Biological therapies in otology |
| Q50311608 | Biological therapies in otology. German version |
| Q35990040 | Candidate-based proteomics in the search for biomarkers of cardiovascular disease |
| Q37533151 | Cardiovascular Effects of Erythropoietin |
| Q83825682 | Cell therapy for ischaemic stroke |
| Q54570378 | Cerebral ischemic tolerance induced by 3-nitropropionic acid is associated with increased expression of erythropoietin in rats. |
| Q21032453 | Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome |
| Q38185249 | Cerebral neovascularization in diabetes: implications for stroke recovery and beyond |
| Q36484538 | Cerebral preconditioning and ischaemic tolerance |
| Q35876807 | Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients |
| Q34591366 | Clinical and experimental advances in regeneration of spinal cord injury |
| Q24201855 | Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke |
| Q24245166 | Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke |
| Q24245243 | Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke |
| Q35777054 | Comparison of acute versus convalescent stage high-sensitivity C-Reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietin |
| Q45300310 | Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains |
| Q36999068 | Control of erythropoietin gene expression and its use in medicine |
| Q38713708 | Current rehabilitation strategy: clinical evidence for erection recovery after radical prostatectomy |
| Q37097716 | Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys |
| Q34596211 | Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. |
| Q83104026 | Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure |
| Q34479931 | Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial |
| Q90123049 | Development of a Neuroprotective Erythropoietin Modified with a Novel Carrier for the Blood-Brain Barrier |
| Q31143549 | Development of new stroke therapies: outlook for neuroprotective drugs |
| Q91714371 | Diagnostic Value of Serum Biomarkers for Differentiating Central and Peripheral Causes of Acute Vertigo |
| Q35440761 | Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain |
| Q34081831 | Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke |
| Q51971879 | Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. |
| Q34567935 | Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise |
| Q35219021 | Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair. |
| Q33428495 | Does diffusion-weighted imaging represent the ischemic core? An evidence-based systematic review. |
| Q35813472 | Does erythropoietin protect the preterm brain? |
| Q35194540 | Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats |
| Q39874402 | EPO for stroke therapy - Is there a future for further clinical development? |
| Q57911490 | EPO's rescue mission in acute myocardial infarction: still more hopes than evidence |
| Q43158426 | Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). |
| Q94999820 | Editorial comment |
| Q35566925 | Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. |
| Q35558158 | Effect of erythropoietin therapy on clinical outcome in patients after acute ischemic stroke: a debatable issue |
| Q46940990 | Effect of recombinant erythropoietin on ischemia-reperfusion-induced apoptosis in rat liver |
| Q36631073 | Effects of Human Erythropoietin on Functional Outcome of Patients with Traumatic Cervical Cord Injury; A Pilot Randomized Clinical Trial |
| Q91955525 | Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion |
| Q38629057 | Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice |
| Q42690125 | Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury |
| Q33726150 | Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial |
| Q41467848 | Electroacupuncture at GV20 and ST36 Exerts Neuroprotective Effects via the EPO-Mediated JAK2/STAT3 Pathway in Cerebral Ischemic Rats. |
| Q33893649 | Endothelial progenitor cells transplantation attenuated blood-brain barrier damage after ischemia in diabetic mice via HIF-1α. |
| Q33924691 | Enhanced Delivery of Erythropoietin Across the Blood-Brain Barrier for Neuroprotection against Ischemic Neuronal Injury |
| Q34056625 | Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury |
| Q48135959 | Epo is involved in angiogenesis in human glioma |
| Q59403261 | Epoetin alfa has potential efficacy in central nervous system disorders |
| Q37905577 | Erectile preservation following radical prostatectomy |
| Q37808657 | Erythropoetin as a novel agent with pleiotropic effects against acute lung injury |
| Q48259869 | Erythropoiesis and neuroprotection: two sides of the same coin? |
| Q37098040 | Erythropoietic agents and the elderly |
| Q37833828 | Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models |
| Q86260187 | Erythropoietin |
| Q86893314 | Erythropoietin |
| Q35801886 | Erythropoietin (epoetin) as a protective factor for the brain |
| Q37781871 | Erythropoietin 2nd cerebral protection after acute injuries: A double-edged sword? |
| Q34336393 | Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice |
| Q37115501 | Erythropoietin Levels Increase during Cerebral Malaria and Correlate with Heme, Interleukin-10 and Tumor Necrosis Factor-Alpha in India |
| Q50551834 | Erythropoietin Protects Rat Brain Injury from Carbon Monoxide Poisoning by Inhibiting Toll-Like Receptor 4/NF-kappa B-Dependent Inflammatory Responses. |
| Q33907747 | Erythropoietin action in stress response, tissue maintenance and metabolism |
| Q34200868 | Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver |
| Q34063671 | Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages |
| Q37174891 | Erythropoietin and polyneuropathy in older persons |
| Q33761779 | Erythropoietin and the effect of oxygen during proliferation and differentiation of human neural progenitor cells. |
| Q92877211 | Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases |
| Q35831214 | Erythropoietin as an antiapoptotic, tissue-protective cytokine. |
| Q35554405 | Erythropoietin both protects from and reverses experimental diabetic neuropathy |
| Q37599397 | Erythropoietin but not VEGF has a protective effect on auditory hair cells in the inner ear. |
| Q82251921 | Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis |
| Q34544348 | Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways |
| Q48241845 | Erythropoietin enhances hippocampal response during memory retrieval in humans. |
| Q28477706 | Erythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathy |
| Q36789003 | Erythropoietin facilitates resuscitation from ventricular fibrillation by signaling protection of mitochondrial bioenergetic function in rats |
| Q47574345 | Erythropoietin for subarachnoid hemorrhage: is there a reason for hope? |
| Q37797743 | Erythropoietin for the treatment of subarachnoid hemorrhage: a review. |
| Q33666585 | Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor |
| Q35147461 | Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial |
| Q50902090 | Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. |
| Q35909929 | Erythropoietin in brain development and beyond |
| Q40227953 | Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease |
| Q37109255 | Erythropoietin in heart and vessels: focus on transcription and signalling pathways |
| Q37334021 | Erythropoietin in spinal cord injury |
| Q47672113 | Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain |
| Q24800397 | Erythropoietin in the critically ill - is it more than just blood? |
| Q42154729 | Erythropoietin in the critically ill: do we ask the right questions? |
| Q35574024 | Erythropoietin in the intensive care unit: beyond treatment of anemia |
| Q36728816 | Erythropoietin in the neurology ICU |
| Q40117988 | Erythropoietin induces positive inotropic and lusitropic effects in murine and human myocardium |
| Q42132275 | Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy |
| Q37571920 | Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor |
| Q37597947 | Erythropoietin modulates the neural control of hypoxic ventilation |
| Q37068999 | Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection |
| Q34164787 | Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma! |
| Q33482074 | Erythropoietin overrides the triggering effect of DNA platination products in a mouse model of cisplatin-induced neuropathy |
| Q82612087 | Erythropoietin prevents nitric oxide and cathepsin-mediated neuronal death in focal brain ischemia |
| Q42916923 | Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis |
| Q35697337 | Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis |
| Q31096583 | Erythropoietin protects from post-traumatic edema in the rat brain. |
| Q28573061 | Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span |
| Q35181502 | Erythropoietin reduces neuronal cell death and hyperalgesia induced by peripheral inflammatory pain in neonatal rats |
| Q46624487 | Erythropoietin regulates hypoxic ventilation in mice by interacting with brainstem and carotid bodies |
| Q47873221 | Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. |
| Q33262324 | Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice |
| Q28212816 | Erythropoietin: a candidate compound for neuroprotection in schizophrenia |
| Q42922791 | Erythropoietin: a multimodal neuroprotective agent |
| Q51749703 | Erythropoietin: a novel treatment for traumatic optic neuropathy-a pilot study. |
| Q38255341 | Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection |
| Q35956310 | Erythropoietin: novel approaches to neuroprotection in human brain disease |
| Q26999392 | Erythropoietin: powerful protection of ischemic and post-ischemic brain |
| Q35949322 | Erythropoietin: still on the neuroprotection road |
| Q42972651 | Erythropoietin: when liability becomes asset in neurovascular repair |
| Q36846925 | Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients. |
| Q48925883 | Gene induction, protein synthesis, and related issues |
| Q34117531 | General anesthetics inhibit erythropoietin induction under hypoxic conditions in the mouse brain |
| Q48417804 | Growth factor-stimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats |
| Q27005953 | Growth factors for the treatment of ischemic brain injury (growth factor treatment) |
| Q35216143 | Growth factors in ischemic stroke. |
| Q35777630 | HIF1 and oxygen sensing in the brain |
| Q38608377 | Harms of off-label erythropoiesis-stimulating agents for critically ill people |
| Q37017179 | Harnessing hypoxic adaptation to prevent, treat, and repair stroke. |
| Q81760527 | Heat acclimation increases hypoxia-inducible factor 1alpha and erythropoietin receptor expression: implication for neuroprotection after closed head injury in mice |
| Q36873773 | Heat acclimation: a unique model of physiologically mediated global preconditioning against traumatic brain injury |
| Q45122705 | High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies |
| Q36497456 | High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. |
| Q34974570 | High plasma erythropoietin levels are associated with prolonged coma duration and increased mortality in children with cerebral malaria |
| Q50873430 | High-dose erythropoietin during cardiac resuscitation lessens postresuscitation myocardial stunning in swine. |
| Q37630654 | Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke |
| Q37667292 | Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection |
| Q36045209 | Hypoxic preconditioning protects against ischemic brain injury |
| Q33657749 | Impaired expression of neuroprotective molecules in the HIF-1alpha pathway following traumatic brain injury in aged mice |
| Q37572370 | Implications of vascular endothelial growth factor for postischemic neurovascular remodeling. |
| Q38403090 | Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin |
| Q33825380 | Increased fetal plasma and amniotic fluid erythropoietin concentrations: markers of intrauterine hypoxia |
| Q38345573 | Interplay between endothelin and erythropoietin in astroglia: the role in protection against hypoxia |
| Q36832872 | Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses |
| Q54528757 | Intracardiac erythropoietin injection reveals antiinflammatory potential and improved cardiac functions detected by Forced Swim Test. |
| Q33937354 | Involvement of erythropoietin in retinal ischemic preconditioning. |
| Q28388335 | Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases |
| Q42762679 | Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way? |
| Q35126696 | Ischemic tolerance and endogenous neuroprotection |
| Q36577097 | Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin |
| Q36739426 | Molecular and cellular immune mediators of neuroprotection |
| Q28080772 | Molecular mechanisms of ischemic preconditioning in the kidney |
| Q36216362 | Molecular targets in spinal cord injury |
| Q33938994 | Mouse models of neurological disorders: a view from the blood-brain barrier |
| Q37358654 | Multifunctional actions of approved and candidate stroke drugs |
| Q36993016 | Multiple doses of erythropoietin impair liver regeneration by increasing TNF-alpha, the Bax to Bcl-xL ratio and apoptotic cell death |
| Q36342072 | Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury |
| Q38086170 | Myocardial infarction: cardioprotection by erythropoietin |
| Q33870071 | Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study |
| Q37085039 | Neural stem cells in the mammalian brain |
| Q37122158 | Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. |
| Q35872654 | Neurological diseases as primary gliopathies: a reassessment of neurocentrism |
| Q21129480 | Neuroplasticity and the next wave of antidepressant strategies |
| Q48176970 | Neuroprotection after major cardiovascular surgery. |
| Q26853031 | Neuroprotection for stroke: current status and future perspectives |
| Q42223704 | Neuroprotection with or without erythropoiesis; sometimes less is more |
| Q50042158 | Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke |
| Q45086893 | Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. |
| Q37412643 | Neuroprotective effects of erythropoietin against oxidant injury following brain irradiation: an experimental study |
| Q36917794 | Neuroprotective effects of erythropoietin in acute ischemic stroke |
| Q44689674 | Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor |
| Q92016044 | Neuroprotective effects of exogenous erythropoietin in Wistar rats by downregulating apoptotic factors to attenuate N-methyl-D-aspartate-mediated retinal ganglion cells death |
| Q36608810 | Neurorestorative treatment of stroke: cell and pharmacological approaches |
| Q37814534 | Neurorestorative treatments for traumatic brain injury |
| Q92964494 | Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system |
| Q33256941 | Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia |
| Q34295232 | O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. |
| Q30777067 | Obligatory role of inducible nitric oxide synthase in ischemic preconditioning |
| Q28570180 | Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons |
| Q37914865 | Oxygen sensing, homeostasis, and disease |
| Q34691239 | Pathologically activated therapeutics for neuroprotection |
| Q35956294 | Pathophysiology of stroke: lessons from animal models |
| Q48539670 | Perioperative erythropoietin protects the CNS against ischemic lesions in patients after open heart surgery |
| Q41911525 | Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats |
| Q34440453 | Pharmacologic preconditioning: translating the promise |
| Q92503914 | Pharmacological Attenuation of Electrical Effects in a Model of Compression Neuropathy |
| Q37024492 | Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly |
| Q36320562 | Platelet decline as a predictor of brain injury in HIV infection |
| Q36144411 | Pleiotropic renal actions of erythropoietin |
| Q41809264 | Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia |
| Q37653695 | Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury. |
| Q42593705 | Potential of Novel EPO Derivatives in Limb Ischemia |
| Q37158226 | Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. |
| Q50989985 | Pretreatment with erythropoietin attenuates the neurological injury after spinal cord ischemia. |
| Q34504572 | Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? |
| Q48096160 | Promoting neuroregeneration after perinatal arterial ischemic stroke: Neurotrophic factors and mesenchymal stem cells |
| Q54975778 | Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease. |
| Q41333380 | Protective effect of erythropoietin against 1-methyl-4-phenylpyridinium-induced neurodegenaration in PC12 cells |
| Q45217981 | Protective effects of erythropoietin on endotoxin-related organ injury in rats |
| Q36301135 | Realizing the clinical potential of ischemic preconditioning and postconditioning. |
| Q48616675 | Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents |
| Q24649547 | Recent trends in erythropoietin-mediated neuroprotection |
| Q41173431 | Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis |
| Q35190989 | Recombinant erythropoietin in clinical practice |
| Q38432879 | Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility |
| Q36481623 | Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria |
| Q34960679 | Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling |
| Q36950700 | Recovery of function in humans: cortical stimulation and pharmacological treatments after stroke |
| Q48474323 | Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives |
| Q57161682 | Regenerative Medicine Therapies for Targeting Neuroinflammation After Stroke |
| Q53296464 | Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model |
| Q33879330 | Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection |
| Q36836773 | Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. |
| Q36153802 | Role of erythropoietin in the brain |
| Q36415946 | Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice |
| Q37190629 | Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration |
| Q36943612 | Role of signal transducer and activator of transcription-3 in estradiol-mediated neuroprotection |
| Q42413212 | Safety and Efficacy of Erythropoietin in Traumatic Brain Injury Patients: A Pilot Randomized Trial |
| Q37295436 | Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali |
| Q24799799 | Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? |
| Q36625386 | Serum erythropoietin and outcome after ischaemic stroke: a prospective study |
| Q39888981 | Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment |
| Q38742380 | Stem cell transplantation therapy for multifaceted therapeutic benefits after stroke |
| Q37053159 | Stem cells and neurological diseases. |
| Q81969481 | Stroke recovery and rehabilitation |
| Q37392519 | Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner |
| Q34725972 | Survival and proliferative roles of erythropoietin beyond the erythroid lineage |
| Q36545939 | TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury |
| Q37794392 | Targeting Astrocytes for Stroke Therapy |
| Q47976704 | The AKT/mTOR pathway mediates neuronal protective effects of erythropoietin in sepsis |
| Q89620015 | The Many Facets of Erythropoietin Physiologic and Metabolic Response |
| Q36167596 | The anaemia of cancer: death by a thousand cuts |
| Q42704983 | The antioxidant effect of erythropoietin on thalassemic blood cells |
| Q48341750 | The approximate planimetric method: a simple, rapid and reliable method for estimation of lesion size in acute ischemic stroke |
| Q54270406 | The combination of insulin-like growth factor 1 and erythropoietin protects against ischemic spinal cord injury in rabbits. |
| Q45791544 | The erythropoietin neuroprotective effect: assessment in coronary artery bypass graft surgery (TENPEAKS) – a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial |
| Q33303476 | The hematopoietic factor GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of adult neural stem cells in vitro |
| Q34193545 | The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI. |
| Q35844081 | The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats |
| Q37871453 | The neurobiology of erythropoietin |
| Q46642580 | The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush |
| Q48962012 | The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin |
| Q37195742 | The role of erythropoietin as an inhibitor of tissue ischemia |
| Q38264699 | The role of erythropoietin in aneurysmal subarachnoid haemorrhage: from bench to bedside |
| Q36762639 | The therapeutic potential of gene transfer for the treatment of peripheral neuropathies |
| Q41859996 | Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit |
| Q37358669 | Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system |
| Q95810354 | Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome |
| Q41838949 | Thrombopoietin Protects the Brain and Improves Sensorimotor Functions: Reduction of Stroke-Induced MMP-9 Upregulation and Blood—Brain Barrier Injury |
| Q41457930 | Time-dependent effect of combination therapy with erythropoietin and granulocyte colony-stimulating factor in a mouse model of hypoxic-ischemic brain injury. |
| Q40292313 | Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain |
| Q57109221 | Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity |
| Q49546137 | Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi-experimental trial. |
| Q57271980 | Treating stroke in the 21st century |
| Q37180432 | Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. |
| Q37997539 | Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. |
| Q34240109 | Trophic factors and stem cells for promoting recovery in stroke. |
| Q61866159 | Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS) |
| Q42921510 | Up‐regulation of erythropoietin receptor by nitric oxide mediates hypoxia preconditioning |
| Q36657959 | Where the Epo cells are. |
| Q37317235 | Year in review 2007: Critical Care--shock |
| Q80476780 | [Neuromonitoring with S-100 protein in the intensive care unit] |
| Q87447444 | [New aspects in the therapy of multiple sclerosis and optic neuritis] |
| Q81450014 | [Therapeutically induced arteriogenesis in the brain. A new approach for the prevention of cerebral ischemia with vascular stenosis] |
| Q35602819 | pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders |
| Q35089582 | rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial. |
Search more.